Literature DB >> 26259877

Prognostic significance of the lymphocyte-to-monocyte ratio in patients with malignant pleural mesothelioma.

Tomoko Yamagishi1, Nobukazu Fujimoto2, Hideyuki Nishi3, Yosuke Miyamoto1, Naofumi Hara1, Michiko Asano1, Yasuko Fuchimoto1, Sae Wada1, Kenichi Kitamura1, Shinji Ozaki1, Takumi Kishimoto4.   

Abstract

OBJECTIVES: Chronic inflammation plays a key role in the pathogenesis of malignant pleural mesothelioma (MPM) as a result of asbestos exposure. Several inflammation-based prognostic scores including the lymphocyte-to-monocyte ratio (LMR), Glasgow Prognostic Score (GPS), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) reportedly predict survival in many malignancies, while the role of LMR in MPM remains unclear. The aim of this study was to evaluate the clinical value of LMR and to compare the prognostic value of these inflammation-based scores in predicting overall survival (OS) in MPM.
MATERIALS AND METHODS: One hundred and fifty patients with histologically proven MPM were included in this retrospective study. Kaplan-Meier curves and multivariate Cox-regression analyses were calculated for OS. The area under the receiver operating characteristics curve (AUC) was calculated to compare the discriminatory ability of each scoring system.
RESULTS: An elevated LMR was significantly associated with prolonged OS. Patients with LMR <2.74 had significantly poor survival compared with LMR ≥2.74 (median, 5.0 versus 14.0 months; p=0.000). The LMR consistently had a higher AUC value at 6 months (0.722), 12 months (0.712), and 24 months (0.670), compared with other scores. Multivariate analysis showed that the LMR was independently associated with OS.
CONCLUSIONS: The LMR is an independent prognostic marker for OS in patients with MPM and is superior to other inflammation-based prognostic scores with respect to prognostic ability.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Asbestos; Lymphocyte-to-monocyte ratio; Malignant pleural mesothelioma; Prognostic score

Mesh:

Substances:

Year:  2015        PMID: 26259877     DOI: 10.1016/j.lungcan.2015.07.014

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  20 in total

Review 1.  Diagnosis and prognosis-review of biomarkers for mesothelioma.

Authors:  Huan H Sun; Allen Vaynblat; Harvey I Pass
Journal:  Ann Transl Med       Date:  2017-06

2.  Mesothelioma diagnosis and prognosis, are we moving beyond histology and performance status towards circulating biomarkers?

Authors:  Oluf Dimitri Røe
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

3.  The prognostic value of lymphocyte-to-monocyte ratio in retinopathy of prematurity.

Authors:  Yu-Xiang Hu; Xiao-Xuan Xu; Yi Shao; Gao-Le Yuan; Feng Mei; Quan Zhou; Yi Cheng; Jun Wang; Xiao-Rong Wu
Journal:  Int J Ophthalmol       Date:  2017-11-18       Impact factor: 1.779

4.  HDAC Inhibition with Valproate Improves Direct Cytotoxicity of Monocytes against Mesothelioma Tumor Cells.

Authors:  Clotilde Hoyos; Alexis Fontaine; Jean-Rock Jacques; Vincent Heinen; Renaud Louis; Bernard Duysinx; Arnaud Scherpereel; Eric Wasielewski; Majeed Jamakhani; Malik Hamaidia; Luc Willems
Journal:  Cancers (Basel)       Date:  2022-04-26       Impact factor: 6.575

5.  Prognostic value of the lymphocyte-to-monocyte ratio and other inflammatory markers in malignant pleural mesothelioma.

Authors:  Abdullah Cetin Tanrikulu; Abdurrahman Abakay; Halil Komek; Ozlem Abakay
Journal:  Environ Health Prev Med       Date:  2016-04-11       Impact factor: 3.674

6.  Usefulness of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in hormone-receptor-negative breast cancer.

Authors:  Chao Liu; Zhou Huang; Qiusheng Wang; Bing Sun; Lijuan Ding; Xiangying Meng; Shikai Wu
Journal:  Onco Targets Ther       Date:  2016-07-27       Impact factor: 4.147

7.  Prognostic significance of neutrophil-to-lymphocyte ratio in patients with malignant pleural mesothelioma: a meta-analysis.

Authors:  Nan Chen; Shuai Liu; Lin Huang; Wanling Li; Wenhao Yang; Tianxin Cong; Lin Ding; Meng Qiu
Journal:  Oncotarget       Date:  2017-02-16

8.  Selected patients can benefit more from the management of etoposide and platinum-based chemotherapy and thoracic irradiation-a retrospective analysis of 707 small cell lung cancer patients.

Authors:  Shoubo Cao; Shi Jin; Jing Shen; Jingyan Cao; Hua Zhang; Qingwei Meng; Chunyan Wang; Aiqi Zhang; Pei Zhang; Yan Yu
Journal:  Oncotarget       Date:  2017-01-31

9.  The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: Systematic review and meta-analysis.

Authors:  Ross D Dolan; Jason Lim; Stephen T McSorley; Paul G Horgan; Donald C McMillan
Journal:  Sci Rep       Date:  2017-12-01       Impact factor: 4.379

Review 10.  Clinical staging of malignant pleural mesothelioma: current perspectives.

Authors:  Maria Bonomi; Costantino De Filippis; Egesta Lopci; Letizia Gianoncelli; Giovanna Rizzardi; Eleonora Cerchiaro; Luigi Bortolotti; Alessandro Zanello; Giovanni Luca Ceresoli
Journal:  Lung Cancer (Auckl)       Date:  2017-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.